Expects to announce topline data expected in the November/December timeframe.
Enrolled patients had underlying medical conditions that are known risk factors for dementia that NE3107 has the potential to improve.
Tuesday, September 26, 2023
BioVie near completion of Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.